Cardiff Oncology, Inc. — Director's Dealing 2021

Jul 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-07-12

Reporting Person: Levine James E. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-12	Common Stock	$6.55	A	390000	Acquired	2031-07-12	Stock Options (390000.0)	Direct

Footnotes

F1: 97,500 vest on 7/12/2022. 8,125 vest monthly for 36 months beginning on 8/12/2022 through 7/12/2025.